Introduction
============

Morphologic complete remission (CR), defined by the presence of \<5% bone marrow blasts and recovery of peripheral blood counts, is the long-standing standard for response assessment in acute myeloid leukemia (AML).^[@b1-1020865]--[@b5-1020865]^ Based on estimates of normal marrow cellularity,^[@b6-1020865]^ however, this cutoff allows for the presence of up to 1010 leukemic blasts or more. It is therefore not surprising that relapse remains the major cause of treatment failure among patients who have achieved a morphologic CR.^[@b4-1020865],[@b5-1020865]^ Significant effort has gone into developing tools to identify minimal (or, perhaps more appropriately, measurable) residual disease (MRD), including multi-parametric flow cytometry (MFC) to enumerate myeloid cell populations with immunophenotypic abnormalities, polymerase chain reaction (PCR) to quantify leukemia-associated mutations or RNA transcript levels, and cytogenetic / fluorescence *in situ* hybridization to detect chromosome level changes specific to the malignant clone. Among these modalities, MFC- and PCR-based approaches have the highest sensitivity and are increasingly employed in the clinic.^[@b7-1020865]--[@b12-1020865]^

A large number of studies has demonstrated worse outcomes for patients who have MRD compared to similarly treated patients in whom no MRD can be detected. This relationship has been observed during/after induction and post-remission chemotherapy courses as well as before and after hematopoietic cell transplantation (HCT).^[@b7-1020865]--[@b12-1020865]^ The magnitude of the association between MRD status and risk of relapse varies widely between studies, however, as do the details of the detection methods. In addition to differences in the specifics of the MRD techniques across institutions, there are also differences in cut-points chosen to define MRD positivity, the patient material that is used to perform the MRD assay on (i.e., peripheral blood or bone marrow), and the timing as well as frequency with which MRD assessments are obtained. In this meta-analysis, we focused on MRD assessed immediately before allogeneic HCT in patients with AML, other than acute promyelocytic leukemia (APL). Besides ascertaining the relationship between pre-HCT MRD and post-transplant outcomes, we also investigated whether, and to what degree, the prognostic role of MRD is influenced by the method of MRD detection.

Methods
=======

We searched PubMed/MEDLINE and EMBASE (*Online Supplementary Table S1*) for English language articles published between January 2005 and June 2016 that reported on the association between pre-HCT MRD (by PCR and/or MFC) and post-HCT survival in patients with non-APL AML in morphologic CR. Two authors (S.A.B. and R.B.W.) independently reviewed the search results. We excluded studies with \<15 patients or \<6 months of follow up. If needed, authors of included studies were contacted for additional information. Our search yielded 344 reports, which were screened according to 2009 PRISMA Guidelines ([Figure 1](#f1-1020865){ref-type="fig"}). For studies of interest, we collected data on the number of patients, median/range age, median follow-up time, percentage of patients with adverse-risk cytogenetics (using the classification criteria reported by study authors), percentage of patients receiving myeloablative (MA) *vs.* reduced intensity conditioning (RIC), interval between MRD detection and HCT, and details of the MRD detection method. We assessed risk of bias using an instrument based on the Quality in Prognostic Studies (QUIPS),^[@b13-1020865]^ modified to reflect our judgment about potential biases (*Online Supplementary Table S2*). Finally, we obtained data for leukemia-free survival (LFS), overall survival (OS), and cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) from the date of HCT. We used a hierarchical approach^[@b14-1020865]^ to compare outcomes of MRD^pos^ and MRD^neg^ subjects: (i) when available, we used observed hazard ratios (HRs) and confidence intervals (CIs); (ii) when Kaplan-Meier curves were provided, we used Enguage Digitizer version 4.1 to calculate HRs and CIs based on an established algorithm,^[@b15-1020865]^ and (iii) for articles providing survival data at single time points, we estimated HRs based on exponential decay.

![PRISMA flow diagram for study selection. HCT: hematopoietic cell transplantation; MRD: minimal residual disease.](102865.fig1){#f1-1020865}

We performed a random-effects meta-analysis, with inter-study heterogeneity described using the I^2^ statistic^[@b16-1020865]^ (STATA version 14; StataCorp, College Station, TX, USA). Cut-points between MRD positivity and negativity were based on criteria specified by the individual publications. In one,^[@b17-1020865]^ no cut-point was specified for Wilms Tumor 1 (*WT1*) transcript level. As other studies used cut-points in the range of 50--70 copies/10^4^ reference gene copies,^[@b18-1020865]--[@b20-1020865]^ and as no events were observed at *WT1* levels \<65, a cutoff of 70 was used. In another study^[@b18-1020865]^ that used a *WT1* cutoff of 50, there were no relapses in the MRD^neg^ group (n=25) by 6.6 years. As no HR could be calculated, this study was not incorporated into pooled CIR results. In two studies in which HRs were extracted from survival curves,^[@b21-1020865],[@b22-1020865]^ curves were portrayed for subgroups within MRD^pos^ and MRD^neg^ patients; here, a weighted average of the HR between groups by number of patients per group was used to obtain a final HR. In one study^[@b19-1020865]^ reporting results by MFC and by *WT1* PCR, we used MFC results for overall analysis, as these data were more complete.

Subgroup analyses involved stratification by MRD detection method, age, and conditioning intensity. We calculated the ratio of the percentage of patients with adverse cytogenetics in the MRD^pos^ and MRD^neg^ groups. If HRs for survival outcomes were higher in studies where this ratio was greater, it would indicate that adverse cytogenetics might be an independent negative prognostic factor.^[@b23-1020865]^ We used meta-regression to test this hypothesis.

Results
=======

Included studies
----------------

Our search yielded 19 unique publications with a total of 1,431 patients ([Table 1](#t1-1020865){ref-type="table"}).^[@b17-1020865]--[@b19-1020865],[@b21-1020865],[@b22-1020865],[@b24-1020865]--[@b37-1020865]^ Details of transplant and conditioning regimens are shown in the *Online Supplementary Table S3*. The sole method of MRD detection was MFC in 9 studies^[@b22-1020865],[@b24-1020865],[@b26-1020865]--[@b29-1020865],[@b33-1020865],[@b36-1020865],[@b37-1020865]^ and *WT1* PCR in 5,^[@b17-1020865],[@b18-1020865],[@b30-1020865]--[@b32-1020865]^ while one study reported results separately for MFC- and *WT1* PCR-based detection.^[@b19-1020865]^ Four studies used combination methods;^[@b21-1020865],[@b25-1020865],[@b34-1020865],[@b35-1020865]^ all of these included MFC, and 3 also included PCR-based detection. Among studies using MFC-based detection, the cut-point between MRD positivity and negativity was fairly uniform: 11 of 14 used the limit of detection for the assay (around 0.1%), while 3 specified a cutoff of 0.1%,^[@b26-1020865],[@b33-1020865],[@b36-1020865]^ which corresponded roughly to the limit of detection in these cases. In other words, heterogeneity in cut-points was primarily determined by differences in performance characteristics and interpretation of the assay rather than the cut-points selected. Among studies that only used PCR-based methods, all assessed quantitative PCR for *WT1*, while one study^[@b31-1020865]^ utilized a panel of other genes in addition to *WT1*. Two studies, both using combination approaches for MRD detection, targeted PCR at AML-specific mutations (e.g., Fms related tyrosine kinase 3 internal tandem duplication \[*FLT3/ITD*\])^[@b21-1020865]^ or fusions genes (e.g., *RUNX1/RUNX1T1*)^[@b25-1020865]^ present at diagnosis. Among studies quantifying *WT1* transcript levels, most normalized against expression of *ABL1*; MRD^pos^ cutoff levels varied between 50--70 copies of *WT1* per 10^4^ copies of *ABL1*.^[@b17-1020865],[@b19-1020865],[@b32-1020865],[@b34-1020865]^

###### 

Characteristics of included studies.
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Five studies were considered as having a high risk of bias: the MRD measurement technique was implicated in all cases, and study confounding was felt possible in 2 of these cases ([Figure 2](#f2-1020865){ref-type="fig"}). For 11 studies, we were able to obtain HRs for all reported outcomes from the manuscript or personal communication; for the other 8 studies, HRs were extrapolated from Kaplan-Meier curves or survival point estimates (n=4).^[@b18-1020865],[@b26-1020865],[@b34-1020865],[@b36-1020865]^ MRD was measured within 60 days of HCT in all studies in which this information was reported, and within 30 days in all but one study.^[@b35-1020865]^

![Risk of bias assessment illustrating review authors' judgments about each risk of bias item for each included study.](102865.fig2){#f2-1020865}

Association between pre-HCT MRD status and post-HCT outcomes
------------------------------------------------------------

Overall, MRD positivity was associated with worse LFS (HR=2.76 \[1.90--4.00\], I^2^=70.0%), OS (HR=2.36 \[1.73--3.22\], I^2^=59.7%), and CIR (HR=3.65 \[2.53--5.27\], I^2^=37.9%) but not NRM (HR=1.12 \[0.81--1.55\], I^2^\<0.1%). After removing studies with a high risk of bias in any domain, MRD remained strongly associated with worse LFS (HR=3.24 \[2.17--4.83\], I^2^=64.5%), OS (HR=2.64 \[1.87--3.72\], I^2^=57.8%), and CIR (HR=4.06 \[2.70--6.12\], I^2^=48.0%) while, again, there was no statistically significant association with NRM (HR=1.18 \[0.80--1.75\] I^2^=0.9%).

Effect of MRD detection method on post-HCT outcomes
---------------------------------------------------

In subgroup analyses, being MRD^pos^ was associated with an increased risk of relapse and mortality regardless of the detection method ([Table 2](#t2-1020865){ref-type="table"}). For CIR, the HR for *WT1* PCR-based methods was statistically significantly larger than for MFC-based methods. [Figure 3](#f3-1020865){ref-type="fig"} shows a forest plot for the 17 studies reporting on the primary outcome of LFS, while similar plots for OS, CIR, and NRM can be found in the *Online Supplementary Figures S1--S3*. Results for studies using MFC-based methods were more heterogeneous than those using *WT1* PCR or combination methods for LFS (I^2^=75.1% *vs.* \<0.1% and 57.2%), OS (I^2^=67.8% *vs.* \<0.1% and 12.5%), and CIR (I^2^=22.1% *vs.* \<0.1% and 6.7%). After excluding studies with a high risk of bias in any domain, *WT1* PCR-based studies and combination methods continued to have low heterogeneity for LFS, OS, and CIR (all I^2^\<0.1%), whereas MFC-based studies showed persistent and considerable heterogeneity for LFS (I^2^=81.5%), OS (I^2^=73.8%), and CIR (I^2^=46.4%).

###### 

Pooled HRs \[95% CI\] and inter-study heterogeneity for all studies (above) and excluding a high risk of bias (below).
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![Forest plot showing hazard ratio (effect size, ES) for leukemia-free survival with pooling of results for each minimal residual disease detection method. Columns indicate study size (N) and whether each study carries a high risk of bias (Bias Risk). Within groups, studies are listed by year of publication. CI: confidence interval; MFC: multi-parametric flow cytometry; PCR: polymerase chain reaction; MRD: minimal residual disease.](102865.fig3){#f3-1020865}

While all MFC-based studies analyzed bone marrow tissue, *WT1* PCR-based studies were mixed between the use of marrow and peripheral blood for analysis. Restriction to studies that reported data from peripheral blood^[@b18-1020865],[@b31-1020865],[@b32-1020865]^ yielded essentially identical results. Outcomes for MFC-based studies were similar regardless of whether residual disease was detected *via* gating for the original leukemia-associated immunophenotype or based on detecting a phenotype different from normal, although results for the latter were more heterogeneous (I^2^ 89.7% *vs.* 32.5% for LFS, 88.3% *vs.* 0.0% for OS, and 70.8% *vs.* 0.0% for CIR). There were no significant differences in outcomes between MFC-based studies by number of fluorochromes (\<6 *vs.* ≥6) used.

Effect of patient age on post-HCT outcomes
------------------------------------------

On subgroup analysis of age 0--20,^[@b18-1020865],[@b25-1020865],[@b26-1020865],[@b30-1020865],[@b36-1020865]^ 21--40,^[@b28-1020865],[@b31-1020865],[@b34-1020865]^ and \>40,^[@b17-1020865],[@b19-1020865],[@b21-1020865],[@b22-1020865],[@b24-1020865],[@b27-1020865],[@b29-1020865],[@b32-1020865],[@b33-1020865],[@b35-1020865]^ we found no difference in the effect of MRD between groups. The same was true after exclusion of studies with a high risk of bias. Among studies reporting on older patients, there was sufficient data to further stratify into ages 40--60 and \>60 for the LFS endpoint; the HR for this outcome was similar in these subgroups (HR=2.67 \[1.46--4.86\], I^2^=81.1%; HR=3.02 \[0.90--10.08\], I^2^=52.3%, respectively). When we restricted our analysis to studies using primarily MA conditioning, 2 were primarily pediatric (median age 0--20),^[@b25-1020865],[@b30-1020865]^ 4 involved young adults (median age 20--40),^[@b27-1020865],[@b28-1020865],[@b31-1020865],[@b34-1020865]^ and 5 involved older adults (median age \>40).^[@b19-1020865],[@b21-1020865],[@b24-1020865],[@b32-1020865],[@b35-1020865]^ The association between MRD and LFS was similar in all age groups, though between-study heterogeneity was high (age 0--20: HR=3.45 \[0.39--30.86\], I^2^=89.5%; age 20--40: HR=2.35 \[1.10--5.02\], I^2^=72%; age \>40: HR=3.56 \[1.79--7.05\], I^2^=77.5%).

Effect of conditioning intensity on post-HCT outcomes
-----------------------------------------------------

Next, we considered whether differences in conditioning regimen intensity might explain between-study heterogeneity, particularly in light of conflicting results from Ustun *et al*.^[@b27-1020865]^ showing in a large cohort (n=203) that MA conditioning could compensate for the increased hazard for relapse and mortality associated with being MRD^pos^, while Walter *et al*.^[@b29-1020865]^ showed no such effect in 241 patients. Among studies reporting LFS as an outcome, 14 reported on the fraction of MRD^pos^ and MRD^neg^ patients who underwent MA *versus* RIC HCT. To test whether higher intensity transplant might reduce the negative impact of being MRD^pos^, we specifically analyzed studies in which \>75% of MRD^pos^ and MRD^neg^ patients received MA HCT (n=12 for LFS endpoint), and compared the results with studies where 0% of patients received MA HCT (n=3 for LFS endpoint). Results from Ustun *et al*.^[@b27-1020865]^ were reported separately for MA and RIC patients within their publication, and for the purposes of this analysis, we treated these sets of results as two separate studies. As shown in [Table 2](#t2-1020865){ref-type="table"} and as a forest plot in the *Online Supplementary Figure S4*, there was no indication that MA conditioning was able to attenuate the negative effects associated with MRD positivity on LFS, OS, or CIR. In contrast, the HRs for MA studies were numerically higher than for the few RIC studies, although the large confidence intervals exclude a definitive conclusion as to whether conditioning intensity affects the association between MRD status and post-HCT outcomes. The exclusion of high-risk studies did not fundamentally change these results and conclusions. Not surprisingly, all studies using RIC conditioning involved older adults (the \>40 age group as stratified above).

Effect of cytogenetic risk on post-HCT outcomes
-----------------------------------------------

Most studies reporting cytogenetics in MRD^pos^ and MRD^neg^ patients used the Southwest Oncology Group^[@b17-1020865],[@b27-1020865],[@b28-1020865],[@b32-1020865],[@b33-1020865]^ or 2010 Medical Research Council criteria,^[@b21-1020865],[@b24-1020865],[@b29-1020865],[@b35-1020865]^ while one incorporated mutational profiling.^[@b34-1020865]^ The ratio of the proportion of adverse-risk cytogenetics among MRD^pos^ to MRD^neg^ patients ranged from roughly equal to 7.5 times higher in the MRD^pos^ group. We used meta-regression to measure how HRs for LFS changed with variations in this risk ratio and found that differences in adverse-risk cytogenetics between MRD^pos^ and MRD^neg^ groups did not account for a significant proportion of between-study variance (R^2^): R^2^ −9.15% (*P*=0.82) for all studies, and 14.83% (*P*=0.92) after excluding high-risk studies ([Figure 4](#f4-1020865){ref-type="fig"}). Results were similar when the study with the highest ratio of 7.5 was excluded from this analysis (*P*=0.62). Similarly, adverse-risk cytogenetics was not an independent prognostic factor for OS (*P*=0.11), CIR (*P*=0.85), or NRM (*P*=0.99).

![Figure 4. Meta-regression analysis showing the effect of the ratio of the percentage of MRD^pos^ patients with adverse cytogenetics to the percentage of MRD^neg^ patients with adverse cytogenetics on log-hazard for leukemia-free survival. A flat line indicates no relationship, and this is shown for all studies (A) and after excluding studies with a high risk of bias (B). MRD: minimal residual disease; HR: hazard ratio.](102865.fig4){#f4-1020865}

Testing for publication bias
============================

Funnel plot analyses for each survival outcome are shown in [Figure 5](#f5-1020865){ref-type="fig"} as a graph of log-HR *versus* the variance in the log-HR. These plots did not suggest a publication bias, although they indicated that the publication of studies considered to have a high risk of bias could bias overall study results towards the null for LFS, OS, and CIR.

![Funnel plot analysis for survival outcomes. Shown are (A) leukemia-free survival (LFS), (B) overall survival (OS), (C) cumulative incidence of relapse (CIR), (D) non-relapse mortality (NRM). HR: hazard ratio.](102865.fig5){#f5-1020865}

Discussion
==========

The findings from this meta-analysis support our main conclusion that the presence of MRD before allogeneic HCT identifies patients at a higher risk of relapse and shorter survival relative to patients in whom no evidence of MRD is found. Although we were unable to incorporate results from one study with an incalculable HR for CIR (based on the lack of relapses among MRD^neg^ patients), the findings from that report similarly supported our conclusion. The association between MRD and post-HCT relapse and mortality is robust, and is seen within all patient ages and regardless of which detection method is used. It is similarly found in those undergoing MA conditioning as well as RIC transplants without discernible difference in strength of association between these cohorts, suggesting that higher conditioning regimen intensity may not be able to overcome the adverse impact of MRD. To the extent that we were able to control for differences in cytogenetic risk with meta-regression, the negative impact of being MRD^pos^ superseded any potential adverse effects of having poor-risk cytogenetics. In comparison, our analysis indicates that pre-HCT MRD is not associated with a significantly increased risk of NRM, in line with the notion that the association between pre-HCT MRD and OS is entirely accounted for by disease relapse without significant contribution from HCT toxicity.

Although our meta-analysis demonstrates a significant association between pre-HCT MRD status and post-HCT outcomes with both *WT1* PCR- and MFC-based assays, we found a greater degree of heterogeneity in survival estimates in studies with MFC-based detection methods. This heterogeneity could not be accounted for by differences in patient age, conditioning regimen intensity, or cytogenetic risk. In addition, the cut-points between MRD positivity and negativity were primarily determined by the limits of detection of each particular assay, indicating that chosen cut-points are unlikely to account for heterogeneity. We were, however, able to show that at least some of this heterogeneity may be accounted for by study-specific differences in approach to MFC, with studies detecting residual disease based on initial leukemia-associated immunophenotypes having more uniform results than those using a "different from normal" approach. Other possible causes of heterogeneity might include site-specific differences in MFC methodology, including differences in antigens and fluorochromes used, methods for cell lysis, number of events collected, or specifics of the aspirate used for analysis, with an increasing risk of hemodilution with each pull. If such speculation is correct, efforts towards standardization/harmonization of MRD methods; as pioneered in acute lymphoblastic leukemia^[@b38-1020865]^ and currently underway for AML; might ultimately lead to less heterogeneous data with MFC-based MRD assays. In contrast, despite some heterogeneity in PCR targets and cut-points, PCR methodology may be relatively more standardized, accounting for more uniform results. As an illustration, the risk estimates for being MRD^pos^ by PCR-quantified *WT1* transcript levels are very similar across several studies, indicating that this method yields highly reproducible results for pre-HCT risk stratification. Even in the smallest studies,^[@b17-1020865],[@b19-1020865]^ in which there was no statistically significant relationship between MRD and LFS, observed HRs were consistent with the other, larger studies. One might wonder whether using more than one method to detect MRD might lead to more sensitive detection and stronger associations with relapse and survival, indicated by higher HRs. We found that studies using combination methods of MRD detection did not show stronger associations with survival outcomes over studies using either MFC- or *WT1* PCR-based methods. That said, all four of these 'combinations' involved MFC-based detection, and the heterogeneity within the combination group may simply underscore the heterogeneity in MFC-based studies as a whole. Alternatively, MFC and *WT1* PCR are both potentially highly sensitive tests, and using multiple modalities may not add much additional sensitivity in detection, or increases in assay sensitivity beyond current limits may not lead to appreciably stronger associations with survival outcomes.

Although our studies highlight the importance of pre-HCT MRD, we were unable to account for inter-study differences in the selection of patients for HCT, which may impact post-HCT results. It is conceivable that different strategies in allocating patients to different post-remission treatment strategies could affect our study results. Given the nature of our analysis, we were only able to test the effects of select covariates and only in an aggregate fashion. Similarly, we were not able to control for the considerable heterogeneity in transplant conditioning regimens, donor sources, graft characteristics, and immunosuppression, all of which could potentially influence relapse and death. Due to absent individual patient data, we were not able to assess whether higher levels of MRD were associated with higher risk of relapse. Regardless of these limitations, our results demonstrate a strong relationship between pre-HCT MRD status and post-HCT relapse and survival, but not NRM. Further studies are needed to determine how pre-HCT MRD status should guide therapeutic decisions, either through treatment intensification for MRD^pos^ patients, or possibly de-intensification for patients who are found to be MRD^neg^ by a reliable method.
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